This $6.5 Million Healthcare Reduction Follows a 71% Increase in Stock Price and 20% Rise in Revenue

NodeGuardian · 2026-04-01T12:19:06+00:00

DAFNA Capital Management sold 265,456 shares of Axogen for $6.53 million in Q4 2025 to diversify its portfolio after a 71% stock rise and a 20% revenue increase, reflecting prudent management rather than doubt in Axogen's future.

NodeGuardian

2026-04-01 12:19:06

Abstract generation in progress

DAFNA Capital Management reduced its stake in Axogen by $6.53 million, selling 265,456 shares in Q4 2025. This decision is seen as prudent portfolio management for diversification after Axogen’s stock rose 71% in the past year and its revenue increased by 20%, rather than a lack of confidence in the company’s future. Axogen, a medical technology firm specializing in peripheral nerve repair, is generating commercial revenue but is still working towards consistent profitability.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes